Post Profile






Mature results favor pembrolizumab as second-line treatment for bladder cancer

(European Society for Medical Oncology) Mature results from the KEYNOTE-045 trial to be presented today at the ESMO 2017 Congress in Madrid have confirmed significantly longer survival in patients with advanced urothelial cancer who receive the checkpoint inhibitor pembrolizumab after initial chemotherapy, compared to an alternative chemotherapy regimen.
read more

share

Related Posts


Ramucirumab plus Docetaxel Improves Progression-free survival in Urothelial Cancer

Health : Newswise Medical News

Ramucirumab plus docetaxel improves progression-free survival in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy, according to late-breaking results from the phase III RANGE ...

Abemaciclib initial therapy improves outcome in endocrine-sensitive advanced breast cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) The results of the MONARCH 3 trial, presented at the ESMO 2017 Congress in Madrid (1), showed that adding the cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib to endocrine therapy impro...

Combination Immunotherapy Improves Kidney Cancer Survival

Health : Newswise Medical News

A combination immunotherapy treatment showed better overall survival in patients with previously untreated advanced or metastatic renal cell carcinoma than current therapy, according to results from a phase 3 clinical trial presente...

Immunotherapy with pembrolizumab deemed cost-effective for advanced melanoma in Hong Kong

Health : EurekAlert: Health

(European Society for Medical Oncology) Immunotherapy with pembrolizumab has been deemed a cost-effective first line treatment for advanced melanoma patients in Hong Kong, researchers report at the ESMO Asia 2016 Congress in Singapo...

Immunotherapy: Promising results in first & second line treatment of metastatic bladder cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) Immunotherapy has shown promising results in first and second line treatment of metastatic bladder cancer in two phase II trials presented at the ESMO 2016 Congress in Copenhagen.

Comments


Copyright © 2016 Regator, LLC